India joined COVAX through a membership with the GAVI alliance.GAVI (The Vaccine Alliance) – India. Retrieved 25 March 2021. The Serum Institute of India is the main producer for the Oxford–AstraZeneca vaccine, up to 700 million doses were expected for 2021. After initial deliveries to North Africa, West Africa, Eastern Europe and the Middle East in March and April 2021, India began to limit vaccine exports until the end of 2021, due to high domestic demand.Beaumont, Peter (24 March 2021) "Delhi reportedly halts AstraZeneca Covid vaccine exports as cases soar". The Guardian. Retrieved 25 March 2021.India coronavirus: Can all adults get vaccinated in 2021? BBC. Retrieved 23 June 2021McGregor, Grady (7 April 2021). "India’s record wave of COVID-19 infections threatens the global vaccine supply". Fortune. Retrieved 9 April 2021. Based on the high infection rates in India, COVAX was projected to deliver only 145 million doses instead of 240 million by May 2021. Vaccine production was also negatively affected because of a ban by the U.S. on the export of key raw materials."Why Covid-19 Vaccination in Poorer Nations Has Slowed, Posing Global Risks". The Wall Street Journal. Retrieved 24 April 2021. In September 2021, the Government of India announced the resumption of vaccines exports from October 2021 onwards since it had quadrupled its production and only excess supplies would be exported.
